WO2011053003A3 - Formulation à rétention gastrique et à libération prolongée contenant de la prégabaline, un oxyde de polyéthylène et un copolymère greffé pva-peg - Google Patents

Formulation à rétention gastrique et à libération prolongée contenant de la prégabaline, un oxyde de polyéthylène et un copolymère greffé pva-peg Download PDF

Info

Publication number
WO2011053003A3
WO2011053003A3 PCT/KR2010/007456 KR2010007456W WO2011053003A3 WO 2011053003 A3 WO2011053003 A3 WO 2011053003A3 KR 2010007456 W KR2010007456 W KR 2010007456W WO 2011053003 A3 WO2011053003 A3 WO 2011053003A3
Authority
WO
WIPO (PCT)
Prior art keywords
polyethyleneoxide
graft copolymer
gastric
sustained release
formulation containing
Prior art date
Application number
PCT/KR2010/007456
Other languages
English (en)
Other versions
WO2011053003A2 (fr
Inventor
Il Hwan Cho
Il Ki Hong
Kyung Min Shin
Da Won Oh
A Ra Ahn
Hyun Jung Noh
Hyun Ah Kang
Hong Chul Jin
Bo Hyun Sung
Original Assignee
Cj Cheiljedang Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Cheiljedang Corporation filed Critical Cj Cheiljedang Corporation
Publication of WO2011053003A2 publication Critical patent/WO2011053003A2/fr
Publication of WO2011053003A3 publication Critical patent/WO2011053003A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

L'invention concerne une formulation à rétention gastrique et à libération prolongée contenant de la prégabaline, ou un sel pharmaceutiquement acceptable de celle-ci, un oxyde de polyéthylène et un copolymère greffé d'alcool polyvinylique/polyéthylène glycol, dans laquelle la propriété de gonflement et la flottabilité de la matrice sont accrues par l'utilisation d'un oxyde de polyéthylène et d'un copolymère greffé d'alcool polyvinylique/polyéthylène glycol, ce qui permet de contrôler la libération du médicament.
PCT/KR2010/007456 2009-10-28 2010-10-28 Formulation à rétention gastrique et à libération prolongée contenant de la prégabaline, un oxyde de polyéthylène et un copolymère greffé pva-peg WO2011053003A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2009-0102539 2009-10-28
KR20090102539 2009-10-28
KR1020100105414A KR101317592B1 (ko) 2009-10-28 2010-10-27 프레가발린, 폴리에틸렌옥사이드 및 폴리비닐알코올-폴리에틸렌글리콜 그라프트 공중합체를 함유하는 위체류형 서방성 제제
KR10-2010-0105414 2010-10-27

Publications (2)

Publication Number Publication Date
WO2011053003A2 WO2011053003A2 (fr) 2011-05-05
WO2011053003A3 true WO2011053003A3 (fr) 2011-09-22

Family

ID=43922835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/007456 WO2011053003A2 (fr) 2009-10-28 2010-10-28 Formulation à rétention gastrique et à libération prolongée contenant de la prégabaline, un oxyde de polyéthylène et un copolymère greffé pva-peg

Country Status (2)

Country Link
KR (1) KR101317592B1 (fr)
WO (1) WO2011053003A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151708A1 (fr) 2010-06-01 2011-12-08 Rubicon Research Private Limited Formes posologiques à rétention gastrique d'analogues de gaba
KR101724024B1 (ko) * 2011-07-26 2017-04-06 주식회사유한양행 2상 방출-제어 시스템에 의한 프레가발린을 함유하는 서방성 정제
KR101438546B1 (ko) * 2011-08-26 2014-09-17 근화제약주식회사 프레가발린을 포함하는 서방성 제제
KR101269829B1 (ko) * 2012-04-27 2013-05-30 씨제이제일제당 (주) 위체류 약물전달 시스템을 이용한 서방성 제제
WO2015114509A1 (fr) * 2014-01-28 2015-08-06 Ranbaxy Laboratories Limited Comprimés à rétention gastrique stabilisée de prégabaline
KR102221846B1 (ko) * 2014-04-07 2021-02-26 영진약품 주식회사 안정성이 개선된 프레가발린을 함유하는 약제학적 조성물 및 이의 제조방법
EP3484456A4 (fr) 2016-07-17 2020-03-18 Mapi Pharma Limited Formes galéniques à libération prolongée de prégabaline
KR102039344B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 경구용 서방성 삼중정제
KR102039345B1 (ko) * 2017-02-01 2019-11-01 지엘팜텍주식회사 프레가발린 함유 고팽윤성 서방성 삼중정제
CN111053749B (zh) * 2018-10-16 2022-07-15 北京泰德制药股份有限公司 一种普瑞巴林缓释组合物及其制备方法
WO2019238068A1 (fr) * 2018-06-13 2019-12-19 北京泰德制药股份有限公司 Composition de prégabaline à libération prolongée et son procédé de préparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070269511A1 (en) * 2005-11-02 2007-11-22 Warner-Lambert Company Llc Solid pharmaceutical compositions containing pregabalin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
JP2011504491A (ja) 2007-11-23 2011-02-10 ルピン・リミテッド プレガバリンの制御放出医薬組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070269511A1 (en) * 2005-11-02 2007-11-22 Warner-Lambert Company Llc Solid pharmaceutical compositions containing pregabalin

Also Published As

Publication number Publication date
WO2011053003A2 (fr) 2011-05-05
KR101317592B1 (ko) 2013-10-15
KR20110046360A (ko) 2011-05-04

Similar Documents

Publication Publication Date Title
WO2011053003A3 (fr) Formulation à rétention gastrique et à libération prolongée contenant de la prégabaline, un oxyde de polyéthylène et un copolymère greffé pva-peg
WO2008132229A3 (fr) Solutions et compositions hautement concentrées en insuline
WO2011049706A8 (fr) Comprimés oralement transformables
WO2009063222A3 (fr) Compositions solides
WO2010125475A3 (fr) Formulations à libération prolongée
WO2006084164A3 (fr) Systeme d'administration a retention gastrique et a liberation lente
WO2010054266A3 (fr) Copolymères multiséquencés
WO2008006528A3 (fr) Nouvelles compositions pharmaceutiques comprenant du lévétiracétam
WO2008037716A3 (fr) Compositions pharmaceutiques
WO2010030598A3 (fr) Formulations pharmaceutiques comprenant du pemetrexed
WO2010009140A3 (fr) Procédés, systèmes et dispositifs destinés à l'administration de dioxyde de chlore
EP3272337A3 (fr) Comprimés
WO2008049657A3 (fr) Utilisation de copolymères de (méth)acrylate dans des formes de médicaments à délivrance retardée pour diminuer les effets de l'éthanol sur la libération de la subtance active
WO2009135593A3 (fr) Formulation pharmaceutique solide à libération retardée
WO2011104652A3 (fr) Compositions vétérinaires
WO2012022919A3 (fr) Formulations à base de nalbuphine et leurs utilisations
WO2014106116A8 (fr) Administration de produits thérapeutiques biologiques
WO2010049449A3 (fr) Nouveaux sels de sunitinib
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2009068708A3 (fr) Composition pharmaceutique à libération prolongée de somatostatine ou d'un analogue de celle-ci
WO2010116382A3 (fr) Compositions pharmaceutiques stables de diclofénac
EP2241310A3 (fr) Formulations à libération modifiée d'émoxypine
WO2009023761A3 (fr) Compositions pharmaceutiques comprenant du ropinirole
WO2007099555A3 (fr) Compositions pharmaceutiques contenant de l'irbésartan
WO2012029074A3 (fr) Compositions pharmaceutiques de linézolide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10827087

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10827087

Country of ref document: EP

Kind code of ref document: A2